Germany Just Ended Insurance Coverage for Cannabis Flower. Most Patients Will Keep Buying, but Not at the Price Insurers Were Paying.

Germany’s GKV-Beitragssatzstabilisierungsgesetz took effect on July 30, 2026, one day after publication in the Federal Law Gazette. Dried cannabis flower is no longer part of the statutory health insurance benefit catalogue under §31(6) SGB V. There is no transition period, and the change applies to patients whose therapy had already been approved. Statutory patients who want to continue on flower can do so only on a private prescription, paying out of pocket.

What remains reimbursable is narrower: standardized cannabis extracts and medicines containing dronabinol or nabilone, for insured patients with serious illness. Cannabis therapy under statutory insurance must now begin with an approved finished medicinal product over a six-month trial period.

The coverage that followed has been loud. The market read underneath it is more measured, and it comes from someone with a decade in the numbers.

Two things are true at once

Alfredo Pascual, Head of Strategy and Corporate Development at Cannamedical Pharma and previously an international analyst at Marijuana Business Daily, laid out the arithmetic in a widely circulated post.

His starting point is that patient harm and market harm are different questions with different answers.

“At the individual level, it can be dramatic. Very sick patients who relied on public health insurance coverage will lose it once the law takes effect. They also lose the only inhalable, fast-acting option covered by insurance. No sugar coating here.”

At the market level, he argues, the numbers describe something calmer. By his reading of GAmSi data, GKV-reimbursed flower came to roughly €125 million in 2025, with a Q4-annualized run rate near €128 million, essentially flat for a year. That works out to about 7.5 tons annually, or roughly 600 kg a month.

Set against a German market he puts at more than 20 tons a month and still growing, reimbursed flower represents about 3% of volume, at most 4%.

And that 3%, in his view, does not evaporate. Pharmacy self-pay prices sit well below illicit-market levels, and self-pay telehealth platforms have already told their users nothing changes for them. His estimate is that most affected patients will switch and pay. If two in three do, the net volume at risk falls to roughly 1%, which a market growing month over month absorbs quickly.

“It’s as if a fast-growing city stopped subsidizing bus tickets for 3% of riders. Those riders won’t just stop riding the bus; most will grumble and buy their own ticket. And the buses won’t stop running.”

Pascual is explicit that the split between switchers and lost volume in his own chart is illustrative rather than measured. Nobody has the switching data yet.

Volume is not margin

Here is where the picture gets more complicated, and where the first hard number has already landed.

Reimbursed prices are not self-pay prices. Pharmacy prices in the statutory channel sit meaningfully above self-pay levels, which is precisely why the pharmacies that specialize in GKV-reimbursed cannabis are the ones most exposed. A patient who switches to a private prescription keeps buying flower, but the revenue attached to that gram, and the margin inside it, both shrink.

Medios AG, the listed pharmaceutical services provider, has already quantified part of that. The company cut its 2026 EBITDA guidance from an expected €94 million to €102 million down to €88 million to €92 million, citing the cannabis reimbursement changes under the BStabG explicitly.

That is one company, and Medios has particular exposure to the specialty pharmacy channel. But it is the first audited number attached to the change, and it points at the gap in the volume argument. Volume can migrate intact while revenue and margin do not.

The extract question, and the rule nobody agrees on

Extracts keep reimbursement but now sit behind the six-month finished-medicinal-product requirement. Pascual puts extract Rezepturen at €80 million for full-year 2025, roughly €85 million on a Q4 run rate, a figure that includes dronabinol preparations. Some of those patients will clear the six-month route and stay covered. Others will move to self-pay flower.

What that transition actually requires is five weeks after the law took effect, still contested. On August 20, the National Association of Statutory Health Insurance Physicians (KBV) said that after further legal review, it considers a cannabis-containing finished medicinal product mandatory for any new cannabis therapy, including outside its approved indication. That reading diverges expressly from the interpretation held by the GKV-Spitzenverband.

Two bodies, one statute, two answers. Meanwhile, the treatment of patients already established on extracts before July 30 rests on an interpretive clarification from the KBV and the GKV-Spitzenverband rather than on any grandfathering provision written into the law itself.

What to watch

The volume thesis is testable, and the test starts now. Three things will settle it.

First, the switching rate. If most affected patients move to private prescriptions, Pascual’s read holds on volume. If a meaningful share simply stops, the picture changes, and the patients most likely to stop are the ones with the least income, which is also the group the law hits hardest.

Second, the margin trail. Medios is the first company to put a number on it. Watch whether other listed players with statutory-channel exposure follow, and by how much.

Third, the interpretive fight. Until the KBV and the GKV-Spitzenverband converge, or the G-BA or the courts settle it, prescribers are operating without a stable rule, and that uncertainty is its own drag on the extract volume that was supposed to survive.

Pascual’s own conclusion is worth keeping in front of all three: a negative signal, real pain for individual patients and for pharmacies built around the reimbursed channel, but not a market-level shock at Germany’s current scale.

The volume argument is strong. The margin argument has not been made yet, and Medios just started making it.

Author’s note: Alfredo Pascual is Head of Strategy and Corporate Development at Cannamedical Pharma, a German pharmaceutical wholesaler of medical cannabis, and has a commercial interest in the German market. He previously spent more than two years as an international analyst at Marijuana Business Daily and has held roles at SEED Innovations, Avextra, and Little Green Pharma. The volume and revenue figures attributed to him are his own analysis of GAmSi and BfArM data, not official statistics, and the split he presents between self-pay switchers and volume at risk is labeled illustrative in his own chart.

Photo by Liv Hema on Unsplash